Open an account

Quantum Biopharma

QNTM · CANADIAN

$2.24−$0.03 (−1.32%)TodayMarket closed ·
Prev close $2.27

About QNTM

Quantum BioPharma Ltd. is a biopharmaceutical company, which engages in building a portfolio of assets and biotech solutions for the treatment of neurodegenerative, inflammatory, metabolic disorders, and alcohol misuse disorders with drug candidates in different stages of development. The firm is engaged in building a portfolio of assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., it is focused on the research and development of its lead compound, Lucid-MS, which is a patented new chemical entity to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis. The firm has also licensed unbuzzd, a formulation of natural ingredients, vitamins, and minerals to help with liver and brain function for the purposes of quickly relieving individuals from the effects of alcohol consumption. The company maintains a portfolio of strategic investments through its wholly owned subsidiary, FSD Strategic Investments Inc., which represents loans secured by residential or commercial property.

Employees
10
Headquarters
TORONTO, Ontario
Listed
May 29, 2018
Sector
Health Care
Industry
Pharmaceuticals
Website
quantumbiopharma.com

QNTM key statistics

Market cap
27.74M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
172.72K
Volume
42.72K
Open price
$2.26
High today
$2.37
Low today
$2.24
52 Week high
$14.86
52 Week low
$2.07

Quantum Biopharma (QNTM) at a glance

As of Oct 23, 2026, Quantum Biopharma (QNTM) shares are priced at $2.24, giving the company a market cap of 27.74M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $2.24 and $2.37. The current price is 0.0% above the day's low and 5.3% below its high.

Volume so far is 42.72K shares, below the average of 172.72K shares a day.

Over the past year Quantum Biopharma has ranged from $2.07 to $14.86, and now sits 1% of the way up that range.

Quantum Biopharma met or beat analyst EPS estimates in 2 of the last 6 quarters. In Q4 FY25 it reported -$0.71 per share against an estimate of $0.00.

The average analyst price target is $32.03, 1329.8% above the current price, from 1 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 1 analyst rating say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 3 analystsAvg $32.03
Low
$31.71
Now
$2.24
High
$32.97

QNTM earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 2 of the last 6 quarters, by 58.5% on average.

  1. Q3 FY19: reported -$143.00 per share against an estimate of -$79.96
  2. Q4 FY19: reported -$177.45 per share against an estimate of -$94.15
  3. Q2 FY20: reported -$43.55 per share against an estimate of -$73.59
  4. Q3 FY20: reported -$89.05 per share against an estimate of -$47.40
  5. Q4 FY20: reported -$22.03 per share against an estimate of -$92.82
  6. Q4 FY25: reported -$0.71 per share against an estimate of $0.00

QNTM news

  • Press releaseGlobe Newswire

    World Renowned Law Firm Grant & Eisenhofer Appointed Lead Counsel In Newly Consolidated Class Action Lawsuit Against Canadian Banks CIBC and RBC Alleging Illegal Stock Market Manipulation of Quantum BioPharma Shares

  • Press releaseGlobe Newswire

    Quantum BioPharma Signs Contract with Thermo Fisher Scientific’s Clinical Research Business to Implement Phase 2 Lucid-MS Trial in Multiple Sclerosis

  • Vandana Singh

    EXCLUSIVE: Thermo Fisher To Support Quantum Biopharma in Progressive Multiple Sclerosis Drug Trial

  • Press releaseGlobe Newswire

    IBN Announces Latest Episode of The BioMedWire Podcast Featuring the Return of Anthony Durkacz, Executive Co-Chair of Quantum BioPharma Ltd.

  • Press releaseGlobe Newswire

    Quantum Biopharma Licensee Unbuzzd Wellness to Advance Clinically Validated Alcohol Metabolism Accelerant After Appointing Zappy as CEO

  • Press releaseGlobe Newswire

    NetworkNewsAudio Announces Audio Press Release (APR) Discussing FDA Clearance for Trial of First-in-Class Treatment Creating ‘Rare Moment’ in MS Research

  • Press releaseGlobe Newswire

    Quantum BioPharma Ltd. (NASDAQ: QNTM) Filling Key Gap in MS Treatment, Cleared by FDA to Launch Historic Trials

  • Press releaseGlobe Newswire

    Historic First in MS Treatment Could Reshape a Multibillion-Dollar Therapeutics Market

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.